NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Cognate is a bit further ahead in prep IMO.

Already expanded clean rooms, personnel, and NWBO still reserves space. Scale up for nGBM volume is not as big as you might think if you break it down to average day to day demand. This is an orphan disease.

Warrant money would enter if trial succeeds.

If SOS were correct, I’d assume the price per share drives up first half 2019 to get within market cap premium range for buyout potential. Mandatory conversion this year would mean if NWBO is delisted (via buyout) after September 13 + 3 days next year, all those shareholders would be long term — aka: tax break, imho.

This is all just extrapolating from SOS’s prediction that there is a fair chance of topline and a BLA filing this fall.